HUP0105154A3 - Use of anticonvulsant derivatives for treating cluster headaches - Google Patents

Use of anticonvulsant derivatives for treating cluster headaches

Info

Publication number
HUP0105154A3
HUP0105154A3 HU0105154A HUP0105154A HUP0105154A3 HU P0105154 A3 HUP0105154 A3 HU P0105154A3 HU 0105154 A HU0105154 A HU 0105154A HU P0105154 A HUP0105154 A HU P0105154A HU P0105154 A3 HUP0105154 A3 HU P0105154A3
Authority
HU
Hungary
Prior art keywords
cluster headaches
anticonvulsant derivatives
treating cluster
treating
anticonvulsant
Prior art date
Application number
HU0105154A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HUP0105154A2 publication Critical patent/HUP0105154A2/hu
Publication of HUP0105154A3 publication Critical patent/HUP0105154A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HU0105154A 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches HUP0105154A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638899P 1999-01-19 1999-01-19
PCT/US2000/000919 WO2000042996A2 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches

Publications (2)

Publication Number Publication Date
HUP0105154A2 HUP0105154A2 (hu) 2002-04-29
HUP0105154A3 true HUP0105154A3 (en) 2004-10-28

Family

ID=22366884

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105154A HUP0105154A3 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches

Country Status (24)

Country Link
US (1) US6319903B1 (hu)
EP (1) EP1143967B1 (hu)
JP (1) JP2002535270A (hu)
KR (1) KR100653326B1 (hu)
CN (1) CN1182845C (hu)
AT (1) ATE279921T1 (hu)
AU (1) AU771388B2 (hu)
BR (1) BR0008176A (hu)
CA (1) CA2359541C (hu)
CZ (1) CZ20012620A3 (hu)
DE (1) DE60015070T2 (hu)
DK (1) DK1143967T3 (hu)
ES (1) ES2228465T3 (hu)
HU (1) HUP0105154A3 (hu)
IL (2) IL144406A0 (hu)
MX (1) MXPA01007350A (hu)
MY (1) MY121486A (hu)
NO (1) NO20013554L (hu)
NZ (1) NZ513115A (hu)
PT (1) PT1143967E (hu)
TR (1) TR200102711T2 (hu)
TW (1) TWI248360B (hu)
WO (1) WO2000042996A2 (hu)
ZA (1) ZA200106786B (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
KR100851955B1 (ko) * 2000-08-17 2008-08-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 통증 및/또는 두통 장애를 치료하거나 방지하기 위한 벨프로익산 아미드 및 2-벨프로에닉산 아미드 유도체의 용도
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20030225002A1 (en) * 2002-02-26 2003-12-04 Livingstone Ian R. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
WO2003080072A1 (en) * 2002-03-18 2003-10-02 Cady Roger K Preemptive prophylaxis of migraine
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2006500377A (ja) 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004071424A2 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Immediate release formulation of n-(2-propylpentanoyl)glycinamide
EP1626707A4 (en) * 2003-02-05 2009-07-01 Yissum Res Dev Co CONTINUOUSLY RELEASE FORMULA OF N- (2-PROPYLPENTANOYL) GLYCINAMIDE, AND ASSOCIATED COMPOUNDS
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AU2005277134A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
US20110117070A1 (en) * 2005-04-19 2011-05-19 Aurora Sheena K Compositions and methods for treating headache
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
EA200702558A1 (ru) * 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
CN102114002B (zh) 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2013139292A1 (zh) 2012-03-23 2013-09-26 中国人民解放军军事医学科学院毒物药物研究所 一种含辛弗林和托吡酯的联合产品
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
BR9712503A (pt) * 1996-10-08 1999-10-19 Ortho Mcneil Pharm Inc Derivados anticonvulsivos úteis no tratamento de dor neuropática

Also Published As

Publication number Publication date
AU771388B2 (en) 2004-03-18
IL144406A0 (en) 2002-05-23
EP1143967A2 (en) 2001-10-17
NO20013554D0 (no) 2001-07-18
TWI248360B (en) 2006-02-01
US6319903B1 (en) 2001-11-20
IL144406A (en) 2006-08-20
HUP0105154A2 (hu) 2002-04-29
ES2228465T3 (es) 2005-04-16
BR0008176A (pt) 2001-11-06
KR100653326B1 (ko) 2006-12-04
WO2000042996A2 (en) 2000-07-27
CA2359541C (en) 2005-06-21
CA2359541A1 (en) 2000-07-27
PT1143967E (pt) 2005-01-31
NZ513115A (en) 2004-11-26
AU2726800A (en) 2000-08-07
NO20013554L (no) 2001-07-18
JP2002535270A (ja) 2002-10-22
CN1182845C (zh) 2005-01-05
EP1143967B1 (en) 2004-10-20
CN1352555A (zh) 2002-06-05
KR20010101595A (ko) 2001-11-14
ATE279921T1 (de) 2004-11-15
DE60015070D1 (de) 2004-11-25
WO2000042996A3 (en) 2000-12-07
TR200102711T2 (tr) 2001-12-21
DK1143967T3 (da) 2005-01-10
ZA200106786B (en) 2002-11-18
DE60015070T2 (de) 2006-01-05
CZ20012620A3 (cs) 2002-09-11
MXPA01007350A (es) 2003-06-06
MY121486A (en) 2006-01-28

Similar Documents

Publication Publication Date Title
HUP0105154A3 (en) Use of anticonvulsant derivatives for treating cluster headaches
HUP0105036A3 (en) Imidazo-quinolin derivatives for treating sexual disturbances
HUP0201393A2 (en) Use of xenon for treating neurointoxications
IL148719A0 (en) Kinase inhibitors as therapeutic agents
HRP20020253A2 (en) Compounds for the treatment of ischemia
HU0001471D0 (en) New method of treatment
SI1176964T1 (sl) Uporaba et743 za zdravljenje raka
GB9821217D0 (en) Treatment for substrates
PL342076A1 (en) Method of treating surfaces
PL350167A1 (en) Medicament for treating hypertension
HUP0202315A2 (en) Process for deacylation of lipodepsipeptides
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
PL350963A1 (en) Use of arylalkanoylpyridazines
HUP0105152A3 (en) Method for treatment of headache
AU1036801A (en) Agent for treating cephalic pain
PL355625A1 (en) Use of formulations for treating surfaces for temporarily improving dirt-removing behavior
HU9904575D0 (en) Process for preparation of n-alkoxy-methyl-acidamides
TW383595U (en) Improvement for foot-sole massager
GB9911183D0 (en) Treatment of cancers
GB9926359D0 (en) Treatment of alopecia
GB9917181D0 (en) Methods of treatment
GB9901310D0 (en) Methods of treatment
SI1268481T1 (sl) Inhibitorji kinaze kot zdravila
SI1068184T1 (en) N-aryloxyethylamine derivatives for the treatment of depression
GB9902367D0 (en) Securable conduits

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees